LifeCycle Pharma Announces Appointment of New Chief Financial Officer

Company Announcement no. 31/2007                                                

To: OMX Nordic Exchange			Hørsholm, Denmark, November 30, 2007

     LifeCycle Pharma Announces Appointment of New Chief Financial Officer      

Hørsholm, Denmark, November 30, 2007; LifeCycle Pharma A/S (OMX: LCP), an       
emerging specialty pharmaceutical company, announced today that it has appointed
Hans Christian Teisen as Senior Vice President and CFO to replace Michael Wolff 
Jensen, Executive Vice President and CFO, who has decided to leave the company, 
effective March 2008.                                                           

Michael Wolff Jensen will leave LifeCycle Pharma to pursue other opportunities. 
He will remain at LifeCycle Pharma through the first half of 2008 to ensure a   
smooth and seamless transition of his roles and responsibilities to the new CFO.

Teisen is currently the Chief Financial Officer with Bavarian Nordic. Prior to  
joining Bavarian Nordic, Teisen was Vice President of Finance, IT, Procurement &
Strategy at Rockwool A/S Denmark. Teisen has worked for The Ministry of Foreign 
Affairs, where he served as Head of Section, Foreign Policy Department in       
Denmark; First Secretary of Embassy, Royal Danish Embassy, London; and Head of  
Section - EU, Maastricht Treaty, EMU and Economic Cooperation.                  

Among Wolff Jensen's key milestones during his tenure, was leading the company  
through a successful IPO in 2006 resulting in a large and international         
shareholder base, participating in closing of several important collaboration   
agreements, including Sciele, Sandoz and Recordati, the approval by the U.S.    
Food and Drug Administration (FDA) of LifeCycle Pharma's novel formulation of   
fenofibrate for the treatment of hyperlipidemia and hypertriglyceridemia and    
positive interim Phase II clinical trial results for LCP-Tacro, an              
immunosuppressant for the treatment of kidney transplant patients, supporting   
the planned initiation of a Phase III clinical trial in 2008.                   

“I would like to thank Michael for his significant efforts and contributions to 
the success of LifeCycle Pharma,” said Dr. Flemming Ørnskov, President and CEO  
of LifeCycle Pharma.  “We are pleased to have attracted a qualified replacement 
for Michael well before his departure and we look forward to having the wealth  
of knowledge and deep financial experience that Hans has to offer our growing   
organization.”                                                                  


About LifeCycle Pharma A/S (“LCP”)                                              
LCP is an emerging specialty pharmaceuticals company that, through innovative   
technologies, is able to rapidly develop a portfolio of differentiated products 
to meet the unique needs of key therapeutic markets and patient populations.    
This includes products for immunosuppression, specifically organ                
transplantation, and to combat certain cardiovascular diseases.  By using its   
unique and patented delivery technology, MeltDose®, LCP is able to develop drugs
with enhanced absorption and thereby increased bioavailability. Currently, the  
Company has a diversified near- and medium-term pipeline, including a product   
ready for US commercialization, five product candidates in clinical trials and  
three in preclinical stages of development. LCP is listed on the OMX Nordic     
Exchange under the trading symbol (OMX: LCP). For further information, please   
visit www.lcpharma.com.                                                         

Contact:                                                                        
Francesca M. DeMartino                                                          
Director, Investor Relations & Corporate Communications                         
(917) 747-4938; FDM@lcpharma.com                                                
                                  ---oo0oo---